Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2018 15:00 ET | Source: Antidote Therapeutics, Inc.

Preclinical proof-of-concept of Antidote Therapeutics’ nicotine-degrading enzyme program as a potential new treatment for nicotine addiction published in BMC Biotechnology

Preclinical studies demonstrated that NicA2 reduces nicotine levels in blood and brain, and extinguishes nicotine self-administration in rats Results support further investigation of optimized...